Batch: Fall 2025
Automated microfluidic platform for activity-based screening of extracellular biomarkers
Contact person: Tiina Sikanen
Batch: Fall 2025
Highly sensitive and scalable immunoassay platform enabling accurate hormone testing for both centralized laboratories and future point-of-care applications
Contact person: Teppo Hyytiä
Batch: Fall 2025
γPNA/MNAzyme as a new tool for rapid and sensitive gene detection in double-strand DNA
Contact person: Hongbo Zhang
Batch: Spring 2025
Modernizing computer-assisted joint replacement surgery with a novel camera-based system
Contact person: Ville Pitkänen & Taneli Tikkakoski
Batch: Spring 2025
From traditional to neurophysiology-guided stroke rehabilitation — we are creating a tool to individualize motor rehabilitation based on each patient's unique functional brain reserve.
Contact person: Miikkael Salmi
Batch: Spring 2025
We are targeting pancreatic cancer's Achilles heel with a groundbreaking and novel mechanism
Contact person: Tuuli Ranki & Firas Hamdan
Batch: Spring 2025
We use transgenic earthworms to turn organic waste into high-value proteins, e.g. antibodies.
Contact person: Michael Jeltsch
Batch: Spring 2025
We aim to create AI models that can diagnose diseases and predict drug efficacy from early-phase histological biopsies based on cellular morphology, whilst avoiding the need for expensive and time-consuming drug assays.
Contact person: Minttu Polso
Batch: Spring 2025
Developing an AI algorithm to remotely detect and monitor health indicators through analysis of speech signals
Contact person: Mikko Petäjä
Batch: Spring 2025
Next generation radiofrequency coils to acquire more data from each MRI scan, enhancing diagnostic and treatment precision.
Contact person: Denis Le Bras
Batch: Spring 2025
We develop a rapid, accurate, and predictive diagnostic platform for early-stage breast cancer and its metastasis.
Contact person: Nonappa
Batch: Spring 2025
Stop Seizures project aims to develop a novel drug with a unique drug target for treating Epilepsy.
Contact person: Ushanandini Mohanraj
Batch: Fall 2024
A novel & ground-breaking drug therapy for ALS
Contact person: Merja Voutilainen
Batch: Fall 2024
Simplifying Glaucoma Care: Monthly Eyedrops for Improved Patient Compliance
Contact person: Stanislav Kalinin
Batch: Fall 2024
AI-based rapid feature extraction transforming medical big brain data into usable format
Contact person: Harri Merisaari
Batch: Fall 2024
Developing an augmented reality solution to empower elderly individuals to live longer, healthier, and more active lives in their own homes.
Contact person: Timo Niskanen
Batch: Fall 2024
Cornea Sense aims to improve cornea health diagnostic by directly measuring cornea hydration levels for better patient outcomes and treatment
Contact person: Anton Chernenko
Batch: Fall 2024
A stand that allows easier casting and better performance in limb procedures.
(Link in Finnish)
Contact person: Pekka Nätti
Batch: Spring 2024
Opportunistic Screening of Alzheimer's Disease Using Retinal Imaging
Contact person: Sebastian Högnabba
Batch: Spring 2024
Developing MYC-dependency targeting drugs to treat cancer
Contact person: Juha Klefström
Batch: Spring 2024
Development of powerful protein-based vaccine technologies
Spin-out to Innofend Oy
Contact person: Minna Hankaniemi
Batch: Spring 2024
A blood test for fast track to stroke treatment
Contact person: Helike Lõhelaid
Batch: Spring 2024
Development of novel cellular stress regulators for the treatment of neurological and metabolic diseases.
Spin-out to ERresQ Oy
Contact person: Vera Kovaleva
Batch: Spring 2024
Pocket sized microscope that solves the challenges faced by research and diagnostic labs.
Contact person: Igor Shevkunov
Batch: Fall 2023
Developing pathophysiologically relevant in vitro models for human neurodegenerative disorders for drug discovery
Turned into a drug development project.
Contact person: Mikko Airavaara
Batch: Fall 2023
A novel, non-invasive approach for cancer screening and diagnosis
Contact person: Andrew Erickson
Batch: Fall 2023
Developing and new tumour-specific agent designed to diagnose and treat metastatic brain tumours.
Contact person: Pirjo Laakkonen
Batch: Fall 2023
Cancer immunotherapy testing on a chip.
Spin-out to Solid Immuno-Oncology Oy
Contact person: Heidi Haikala
Batch: Spring 2023
Developing new immunotherapies for cancer
Contact person: Carlos Rogerio Figueiredo
Batch: Spring 2023
Immunoliposomes to detect rupture prone intracranial aneurysms
Contact person: Behnam Rezai Jahromi
Batch: Spring 2023
Non-invasive method to diagnose intestinal diseases
Contact person: Lauri Polari
Batch: Spring 2023
Intra-articular calcipotriol for treatment of (osteo)arthritis
Contact person: Johanna Huhtakangas
Batch: Spring 2023
Digital therapeutics treatment for fear of childbirth
Contact person: Annika Järvelin
Batch: Spring 2023
DNA Nanoswitches-enabled Visual Colorimetric Diagnostics
Contact person: Jacky Loo
Batch: Spring 2023
Next-generation bioinks for 3D bioprinting living tissues and organs.
Spin-out to LifeGlue Technologies Oy
Contact person: Anni Mörö
Batch: Spring 2023
Improved early-stage cancer detection and sensitive disease monitoring
Project manager moved to University of Zurich.
Contact person: Pyry Helkkula
Batch: Spring 2023
Early intervention for hearing health
Spin-out to Otos Health Oy
Contact person: Tanja Tervonen
Batch: Spring 2023
Novel method for optimized and personalized labor induction care
Contact person: Hanna Castrén-Niemi
Batch: Fall 2022
A smart optical sensor for arthroscopic surgery
Preparing spin-out to a startup.
Contact person: Isaac Afara
Batch: Fall 2022
Graphene based dry electrodes for biometric measurements
Spin-out to Mukava Biosignals Oy
Contact person: Teemu Ruotsalainen
Batch: Fall 2022
Novel biomarker and early drug intervention for Alzheimer's disease
Spin-out to R2therapies Oy
Contact person: Ilkka Fagerlund
Batch: Fall 2022
(Former ER4Surgery) Image-guided surgery without Instruments.
Spin out to Surgerix Oy.
Contact person: Mikko Pitkänen
Batch: Fall 2022
A Novel Cell Growth Matrix by 3D Printing of Biopolymers
Contact person: Chunlin Xu
Batch: Spring 2022
Light- reconfigurable substrate for cell cultures
Contact person: Chiara Fedele
Batch: Spring 2022
Mental health platform and services
Spin-out to Brightlife Oy
Contact person: Eero Haikonen
Batch: Spring 2022
Delivery of encapsulated mitochondria as novel pharmaceutical solution
Contact person: Hongbo Zhang
Batch: Spring 2022
Automated and scalable tool for precision diagnosis and personalized treatment
Spin-out to MultivisionDx Oy
Contact person: Karolina Punovuori
Batch: Fall 2021
AI for the detection of heart transplant rejection.
Product validation continues, spin-out under consideration.
Contact person: Juha Peltonen
Batch: Fall 2021
Novel method for diagnosing respiratory suppression
Spin-out to a non-published startup.
Contact person: Antti Vehkaoja
Batch: Fall 2021
Non-invasive solution to support rehabilitation from AUD.
Spin-out to AlionLife Oy
Contact person: Jukka Planman
Batch: Fall 2021
Diaper embedded biosensor platform, that screens abnormal clinical conditions
Contact person: Oguz Tanzer
Batch: Fall 2021
Prevention of pressure ulcers
Manager was recruited as Team Leader to Attendo.
Contact person: Nuno Nobre
Batch: Fall 2021
Viability analysis of organ transplants, and neuronal and cardiac implants
Preparing spin-out to a startup.
Contact person: Jarno Tanskanen
Batch: Fall 2021
TumorMimic tailors 3D cultures to enable enhanced cancer drug screening
Contact person: Juho Pokki
Batch: Fall 2021
How to make vaccines thermostable
Preparing to spin-out a startup.
Contact person: Manlio Fusciello
Batch: Spring 2021
Rapid diagnostics of human picornaviruses based on viral proteases
Contact person: Petri Susi
Batch: Spring 2021
Novel method for histology.
Solution for commercial use at University of Turku.
Contact person: Ilkka Paatero
Batch: Spring 2021
mTMS – multilocus transcranial magnetic stimulation.
Devices already in use at international pilot customers.
Contact person: Dubravko Kicic
Batch: Spring 2021
Personalized prediction of the risk for aortic dilatation and rupture.
Preparing spin-out to a startup.
Contact person: Marja Hedman
Batch: Spring 2021
Poly(jasmine lactone): A Versatile Platform for Drug Delivery
Contact person: Kuldeep Bansal
Batch: 2020
Method for objective assessment of infant motor development.
Solution in use at BABA Center (HUS) and collaboration with Movesense.
Contact person: Sampsa Vanhatalo
Batch: 2020
Tissue specific therapy for skin diseases.
Licensed to THERAVIA.
Contact person: Tero Järvinen
Batch: 2020
Platform for optimized production of biotechnological proteins
Spin-out to Avenue Biosciences Oy and a startup in the U.S.
Contact person: Ville Paavilainen
Batch: 2020
Functional brain imaging reshaped
Contact person: Marko Havu
Batch: 2020
Smart heart monitoring.
Spin-out to Sonai Health Oy.
Contact person: Arto Kotimaa
Batch: 2020
Cardiac Micrograft Therapy™ for treating Ischhemic Scars and Heart Failure.
Spin-out to EpiHeart Oy.
Contact person: Kai Kronström
Batch: 2020
Accurate correction for QT interval ‒ the most important cardiac risk measure.
Spin-out to Monicardi Oy
Contact person: Esa Räsänen
Batch: 2020
Long-term oral drug delivery.
Alumni due Prof. Helder Santos got recruited as Head of Biomedical Engineering at UMCG (Groningen, NED).
Contact person: Helder Santos
Batch: 2020
Natural medication for human papillomavirus (HPV)-associated warts.
Spin-out to ATB Antivirals Oy (previously Anison Therapeutics)
Contact person: Preethy Paul
Batch: 2020
Functional insight into hypercholesterolemia patients.
Spin-out to Moncyte Oy
Contact person: Simon Pfisterer
Batch: 2020
Personalized treatment planning of osteoarthritis.
Spin-out to MSK Technologies Oy.
Contact person: Joona Kemppainen
Batch: 2020
Implantable support to treat pelvic organ prolapse.
Spin-out to Lignum Medical Oy
Contact person: Eija Raussi-Lehto
Batch: 2020
Indoor air diagnostics with fluorescent C. elegans nematodes.
Lead to a co-research project.
Contact person: Päivi Koskinen
Batch: 2019
Novel treatment for limbal epithelial stem cell deficiency.
Spin-out to StemSight Oy
Contact person: Laura Koivusalo
Batch: 2019
Therapeutics for antimicrobial resistant bacteria.
Spin-out to Arivin Therapeutics Oy, was accepted to INCATE Incubator.
Contact person: Christopher Jonkergouw
Batch: 2019
Distal radius fractures artificial intelligence diagnostic tool.
Preparations for a startup in progress.
Contact person: Jorma Ryhänen
Batch: 2019
Ultrasound solution for cancer biopsies
Technology licensing under preparation.
Contact person: Jouni Rantanen
Batch: 2019
Simple droplet devices for biomedicine, diagnostics and pharma.
Got continuing development funding.
Contact person: Päivi Saavalainen
Batch: 2019
Vertigo diagnostics for primary care.
Got remarkable funding for another project.
Contact person: Tuomas Hyytiä
Batch: 2019
Diagnostic test for vitamin B3 metabolism deficiency.
Spin-out to NADMED Oy
Contact person: Liliya Euro
Batch: 2019
Topographically tuned and sustainable surfaces for biological applications.
Potential licensing case. Project manager got recruited as Innovation Manager at UTU.
Contact person: Erik Niemelä
Batch: Fall 2018
Laboratory and computational method for liquid biopsies.
Spin-out to Genomill Health Oy
Contact person: Manu Tamminen
Batch: Fall 2018
Rational discovery of protein-protein interaction modulators.
Spin-out to Aurlide Oy
Contact person: Olli Pentikäinen
Batch: Fall 2018
Parkinson’s signature biomarker assay.
Ongoing large validation study with Michael J Fox Foundation funding.
Contact person: Eleanor Coffey
Batch: Spring 2018
Light controlled protein production.
An alumni due Project Manager got recruited to Bayer.
Contact person: Jari Rossi
Batch: Spring 2018
Microbiome therapy for Parkinson’s disease.
IP turned into NeuroBiome Oy that has contract with a large company
Contact person: Filip Scheperjans
Batch: Spring 2018
Extra cellular vesicle solution for bleeding disorders.
An alumni due Project Manager got recruited to Mayo Clinic (USA).
Contact person: Mayank Saraswat
Batch: Spring 2018
Method for extra-cellular vesicle (EV) isolation.
Solution in use at EV group at University of Helsinki.
Contact person: Maija Puhka
Batch: Spring 2018
Method to monitor the oxygenation of myocardial tissue.
Spin-out to SpectroCor Oy
Contact person: Kalle Kotilahti
Batch: Spring 2018
Novel heat treatment for age related macular degeneration.
Spin-out to Maculaser Oy
Contact person: Jani Tirronen
Batch: Spring 2018
Microbiome diagnostics for Parkinson’s disease.
IP turned to NeuroBiome Oy that has joint development and licensing agreement.
Contact person: Filip Scheperjans
Batch: Spring 2018
Mycobacterial biofilms as anti-tuberculosis drug targets.
Became a cornerstone of an extensive multinational research program.
Contact person: Mataleena Parikka
Batch: Spring 2018
Novel single cell omics methods.
Spin-out to Scellex Oy
Contact person: Päivi Saavalainen
Batch: Spring 2018
Light-activated antimicrobial surfaces and materials.
IP acquired by Plasmonics Oy
Contact person: Alexandre Efimov
Batch: Fall 2017
AI solution for toxicity testing.
Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.
Contact person: Dario Greco
Batch: Fall 2017
Laser solution for eye treatment.
Became a development case for industry.
Contact person: Jukka Viheriälä
Batch: Fall 2017
Toxicity test for heart cells.
Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.
Contact person: Tuula Heinonen
Batch: Fall 2017
Tissue analysis for breast cancer surgery.
Spin-out to Olfactomics Oy
Contact person: Antti Roine
Batch: Spring 2017
Ocular biomarker panel and analysis.
Project manager got recruited to another project.
Contact person: Ulla Aapola
Batch: Spring 2017
Microbiological Analyses on (Blue) Bio- and Circular Economies.
Spin-out to GreenSeq Oy
Contact person: Kirsi-Maarit Lehto
Batch: Spring 2017
Peritoneal diagnostics for dialysis patients.
Spin-out to Kiwecare / Smart PD Solutions Oy
Contact person: Pirgit Silvast-Äikäs
Batch: Pilot 2016 / Spring 2017
Nano structure for bioimaging.
Spin-out to XFold Imaging Oy
Contact person: Timo Jäntti
Batch: Pilot 2016 / Spring 2017
Cancer drug for GIST.
Spin out to Sartar Therapeutics Oy
Contact person: Harri Sihto
Batch: Pilot 2016 / Spring 2017
Caries and infection prevention and treatment.
Spin-out to Koite Health Oy
Contact person: Tommi Pätilä
Batch: Pilot 2016 / Spring 2017
Safety mechanism for surgical drills.
Spin-out to Surgify Medical Oy
Contact person: Visa Sippola
Batch: Spring 2018
Microbiome therapy for Parkinson’s disease.
IP turned into NeuroBiome Oy that has contract with a large company
Contact person: Filip Scheperjans
Batch: Fall 2017
Tissue analysis for breast cancer surgery.
Spin-out to Olfactomics Oy
Contact person: Antti Roine
Batch: Pilot 2016 / Spring 2017
Nano structure for bioimaging.
Spin-out to XFold Imaging Oy
Contact person: Timo Jäntti
Batch: Pilot 2016 / Spring 2017
Caries and infection prevention and treatment.
Spin-out to Koite Health Oy
Contact person: Tommi Pätilä
Batch: Pilot 2016 / Spring 2017
Safety mechanism for surgical drills.
Spin-out to Surgify Medical Oy
Contact person: Visa Sippola
Batch: Fall 2018
Laboratory and computational method for liquid biopsies.
Spin-out to Genomill Health Oy
Contact person: Manu Tamminen
Batch: Fall 2018
Rational discovery of protein-protein interaction modulators.
Spin-out to Aurlide Oy
Contact person: Olli Pentikäinen
Batch: Spring 2018
Light controlled protein production.
An alumni due Project Manager got recruited to Bayer.
Contact person: Jari Rossi
Batch: Spring 2018
Extra cellular vesicle solution for bleeding disorders.
An alumni due Project Manager got recruited to Mayo Clinic (USA).
Contact person: Mayank Saraswat
Batch: Spring 2018
Novel single cell omics methods.
Spin-out to Scellex Oy
Contact person: Päivi Saavalainen
Batch: Fall 2017
Laser solution for eye treatment.
Became a development case for industry.
Contact person: Jukka Viheriälä
Batch: Spring 2017
Peritoneal diagnostics for dialysis patients.
Spin-out to Kiwecare / Smart PD Solutions Oy
Contact person: Pirgit Silvast-Äikäs
Batch: Pilot 2016 / Spring 2017
Cancer drug for GIST.
Spin out to Sartar Therapeutics Oy
Contact person: Harri Sihto
Batch: 2019
Vertigo diagnostics for primary care.
Got remarkable funding for another project.
Contact person: Tuomas Hyytiä
Batch: Spring 2018
Method for extra-cellular vesicle (EV) isolation.
Solution in use at EV group at University of Helsinki.
Contact person: Maija Puhka
Batch: Spring 2018
Method to monitor the oxygenation of myocardial tissue.
Spin-out to SpectroCor Oy
Contact person: Kalle Kotilahti
Batch: Spring 2018
Novel heat treatment for age related macular degeneration.
Spin-out to Maculaser Oy
Contact person: Jani Tirronen
Batch: Spring 2018
Mycobacterial biofilms as anti-tuberculosis drug targets.
Became a cornerstone of an extensive multinational research program.
Contact person: Mataleena Parikka
Batch: Spring 2018
Light-activated antimicrobial surfaces and materials.
IP acquired by Plasmonics Oy
Contact person: Alexandre Efimov
Batch: Fall 2017
Toxicity test for heart cells.
Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.
Contact person: Tuula Heinonen
Batch: Spring 2017
Ocular biomarker panel and analysis.
Project manager got recruited to another project.
Contact person: Ulla Aapola
Batch: Spring 2017
Microbiological Analyses on (Blue) Bio- and Circular Economies.
Spin-out to GreenSeq Oy
Contact person: Kirsi-Maarit Lehto
Batch: 2020
Cardiac Micrograft Therapy™ for treating Ischhemic Scars and Heart Failure.
Spin-out to EpiHeart Oy.
Contact person: Kai Kronström
Batch: 2020
Long-term oral drug delivery.
Alumni due Prof. Helder Santos got recruited as Head of Biomedical Engineering at UMCG (Groningen, NED).
Contact person: Helder Santos
Batch: 2020
Natural medication for human papillomavirus (HPV)-associated warts.
Spin-out to ATB Antivirals Oy (previously Anison Therapeutics)
Contact person: Preethy Paul
Batch: 2020
Personalized treatment planning of osteoarthritis.
Spin-out to MSK Technologies Oy.
Contact person: Joona Kemppainen
Batch: 2019
Novel treatment for limbal epithelial stem cell deficiency.
Spin-out to StemSight Oy
Contact person: Laura Koivusalo
Batch: 2019
Topographically tuned and sustainable surfaces for biological applications.
Potential licensing case. Project manager got recruited as Innovation Manager at UTU.
Contact person: Erik Niemelä
Batch: Spring 2018
Microbiome diagnostics for Parkinson’s disease.
IP turned to NeuroBiome Oy that has joint development and licensing agreement.
Contact person: Filip Scheperjans
Batch: Fall 2017
AI solution for toxicity testing.
Solution in use at FHAIVE, a reference toxicity laboratory for EURL ECVAM.
Contact person: Dario Greco
Batch: 2020
Smart heart monitoring.
Spin-out to Sonai Health Oy.
Contact person: Arto Kotimaa
Batch: 2020
Implantable support to treat pelvic organ prolapse.
Spin-out to Lignum Medical Oy
Contact person: Eija Raussi-Lehto
Batch: 2020
Indoor air diagnostics with fluorescent C. elegans nematodes.
Lead to a co-research project.
Contact person: Päivi Koskinen
Batch: 2019
Therapeutics for antimicrobial resistant bacteria.
Spin-out to Arivin Therapeutics Oy, was accepted to INCATE Incubator.
Contact person: Christopher Jonkergouw
Batch: 2019
Distal radius fractures artificial intelligence diagnostic tool.
Preparations for a startup in progress.
Contact person: Jorma Ryhänen
Batch: 2019
Ultrasound solution for cancer biopsies
Technology licensing under preparation.
Contact person: Jouni Rantanen
Batch: 2019
Simple droplet devices for biomedicine, diagnostics and pharma.
Got continuing development funding.
Contact person: Päivi Saavalainen
Batch: 2019
Diagnostic test for vitamin B3 metabolism deficiency.
Spin-out to NADMED Oy
Contact person: Liliya Euro
Batch: Fall 2018
Parkinson’s signature biomarker assay.
Ongoing large validation study with Michael J Fox Foundation funding.
Contact person: Eleanor Coffey
Batch: Spring 2022
Mental health platform and services
Spin-out to Brightlife Oy
Contact person: Eero Haikonen
Batch: 2020
Platform for optimized production of biotechnological proteins
Spin-out to Avenue Biosciences Oy and a startup in the U.S.
Contact person: Ville Paavilainen
Batch: 2020
Functional brain imaging reshaped
Contact person: Marko Havu
Batch: Fall 2023
Developing pathophysiologically relevant in vitro models for human neurodegenerative disorders for drug discovery
Turned into a drug development project.
Contact person: Mikko Airavaara
Batch: Spring 2023
Digital therapeutics treatment for fear of childbirth
Contact person: Annika Järvelin
Batch: Spring 2023
Next-generation bioinks for 3D bioprinting living tissues and organs.
Spin-out to LifeGlue Technologies Oy
Contact person: Anni Mörö
Batch: Spring 2023
Improved early-stage cancer detection and sensitive disease monitoring
Project manager moved to University of Zurich.
Contact person: Pyry Helkkula
Batch: Fall 2022
A smart optical sensor for arthroscopic surgery
Preparing spin-out to a startup.
Contact person: Isaac Afara
Batch: Fall 2022
Graphene based dry electrodes for biometric measurements
Spin-out to Mukava Biosignals Oy
Contact person: Teemu Ruotsalainen
Batch: Fall 2022
A Novel Cell Growth Matrix by 3D Printing of Biopolymers
Contact person: Chunlin Xu
Batch: Fall 2021
Novel method for diagnosing respiratory suppression
Spin-out to a non-published startup.
Contact person: Antti Vehkaoja
Batch: Fall 2021
Non-invasive solution to support rehabilitation from AUD.
Spin-out to AlionLife Oy
Contact person: Jukka Planman
Batch: Fall 2021
Prevention of pressure ulcers
Manager was recruited as Team Leader to Attendo.
Contact person: Nuno Nobre
Batch: Fall 2021
Viability analysis of organ transplants, and neuronal and cardiac implants
Preparing spin-out to a startup.
Contact person: Jarno Tanskanen
Batch: Fall 2021
How to make vaccines thermostable
Preparing to spin-out a startup.
Contact person: Manlio Fusciello
Batch: Spring 2021
Novel method for histology.
Solution for commercial use at University of Turku.
Contact person: Ilkka Paatero
Batch: Spring 2021
mTMS – multilocus transcranial magnetic stimulation.
Devices already in use at international pilot customers.
Contact person: Dubravko Kicic
Batch: Spring 2021
Personalized prediction of the risk for aortic dilatation and rupture.
Preparing spin-out to a startup.
Contact person: Marja Hedman
Batch: Spring 2021
Poly(jasmine lactone): A Versatile Platform for Drug Delivery
Contact person: Kuldeep Bansal
Batch: 2020
Method for objective assessment of infant motor development.
Solution in use at BABA Center (HUS) and collaboration with Movesense.
Contact person: Sampsa Vanhatalo
Batch: 2020
Tissue specific therapy for skin diseases.
Licensed to THERAVIA.
Contact person: Tero Järvinen
Batch: 2020
Accurate correction for QT interval ‒ the most important cardiac risk measure.
Spin-out to Monicardi Oy
Contact person: Esa Räsänen
Batch: 2020
Functional insight into hypercholesterolemia patients.
Spin-out to Moncyte Oy
Contact person: Simon Pfisterer
Batch: Spring 2024
Development of powerful protein-based vaccine technologies
Spin-out to Innofend Oy
Contact person: Minna Hankaniemi
Batch: Spring 2024
Development of novel cellular stress regulators for the treatment of neurological and metabolic diseases.
Spin-out to ERresQ Oy
Contact person: Vera Kovaleva
Batch: Fall 2023
Cancer immunotherapy testing on a chip.
Spin-out to Solid Immuno-Oncology Oy
Contact person: Heidi Haikala
Batch: Spring 2023
Early intervention for hearing health
Spin-out to Otos Health Oy
Contact person: Tanja Tervonen
Batch: Fall 2022
(Former ER4Surgery) Image-guided surgery without Instruments.
Spin out to Surgerix Oy.
Contact person: Mikko Pitkänen
Batch: Spring 2022
Automated and scalable tool for precision diagnosis and personalized treatment
Spin-out to MultivisionDx Oy
Contact person: Karolina Punovuori
Batch: Fall 2021
AI for the detection of heart transplant rejection.
Product validation continues, spin-out under consideration.
Contact person: Juha Peltonen